ArticleJournal of Alzheimer's disease : JAD2025
Validating a brief performance-based measure of cognition and daily functioning in amnestic mild cognitive impairment and mild Alzheimer's disease.
Article in Journal of Alzheimer's disease : JAD, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting the onset of dementia with longitudinal performance-based measures of physical function.The journals of gerontology. Series B, Psychological sciences and social sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BackgroundThe Clinical Dementia Rating (CDR) scale is widely used as a cognitive and functional measure in Alzheimer's disease (AD) clinical trials. Given its time and personnel burden, there is a need to more efficiently identify patients who warrant further evaluation or clinical trial qualification. To potentially address this need, a novel performance-based test of cognition and daily functioning has been developed for use in AD research and clinical care.ObjectiveTo test whether this novel performance-based test is associated with levels of daily functioning in both impaired and unimpaired individuals.MethodsOne-hundred-seventy-one participants (72 cognitively unimpaired; 53 amnestic mild cognitive impairment; 46 mild AD) completed the novel performance-based test of cognition and daily functioning, as well as the Quick Dementia Rating System (QDRS) for estimating global CDR.ResultsThe novel test was significantly associated with the QDRS Total, as well as the Behavioral and Cognitive subdomains, and differentiated between estimated global CDR scores of 0 versus ≥0.5. No significant effect of age, sex, or education on the performance-based test was observed.ConclusionsThe performance-based test used in this study can be considered a measure of cognition and daily functioning. As such, it may be a quick, objective method for identifying impaired individuals who may qualify for clinical trial enrollment or may warrant further evaluation without the need for informant input.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.